





EVALUATION OF ENHANCED RECOVERY AFTER SURGERY COMBINED WITH BARIATRIC SURGERY TARGETING OPIOID PRESCRIPTIONS PROTOCOLS ON PATIENT OUTCOMES AND LENGTH OF STAY IN BARIATRIC SURGERY

Jeffrey Silverstein MD, Adam Khayat BSc, Patricia Cherasard PHD, Jun Levine MD, Anirudha Goparaju MD, Venkata Kella MD, Islam Shahidul DrPH, Collin E.M. Brathwaite MD, MS



Disclosure

Jeffrey Silverstein, MD.

I do not have any relevant financial relationship(s) with any commercial interest that pertains to the content of my presentation.





Enhanced Recovery After Surgery Protocols (ERAS)





THE OPIOID EPIDEMIC BY THE NUMBERS







10.1 million



people misused prescription opioids in the past year1


people used methamphetamine in the past year1

50,000

people used heroin

for the first time1

0.



1.6 million

people had an opioid use


disorder in the past year1





people misused prescription pain relievers for the first time1

48,006 deaths attributed to overdosing







ending June 2020)³





Bariatric Surgery Targeting Opioid Prescriptions (BSTOP)

- The initiative: reduce opioid prescriptions
 - Pre-operative education
 - Multimodal pain control during all phases of care
 - Regional analgesia
 - Minimize opioid use
 - Data collection phase follow by implementation phase
 - We implemented BSTOP immediately




METABOLIC AND BARIATRIC SURGERY ACCREDITATION AND QUALITY IMPROVEMENT PROGRAM



Our Protocol Highlights

- Pre-operative
 - Patient education
 - Pain and nausea control
- Intra-operative:
 - No induction opiates!
 - Avoid gases
 - Intra-operative TAP Block
- Post-operative
 - Breakthrough opiates by provider only





Methods

- Retrospective review of prospectively maintained-database
- Sleeve gastrectomy and Roux-en-Y gastric bypass patients
 - 12-month period for each group
 - Pre-intervention 8/2018 7/2019
 - Post-intervention 8/2019 10/2020*
- Outcomes: Length of stay and Discharge opioid prescriptions
 - Additional: readmission and complication rate
- Statistical analysis: Poisson regression, SAS 9.4



Results: Demographics

| | Pre Intervention (N=360) | Post Intervention (N=297) | Overall (N=657) | P- value ¹ |
|------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------|
| Demographics | | | | |
| Age (Years) | <mark>44.0 (35.0 - 54.0)</mark> | <mark>47.0 (36.0 - 56.0)</mark> | <mark>45.0 (36.0 - 54.0)</mark> | <mark>0.128</mark> |
| BMI (kg/m2 | <mark>45.7 (41.8 - 51.3)</mark> | <mark>44.7 (40.8 - 51.4)</mark> | <mark>45.4 (41.3 - 51.3)</mark> | <mark>0.281</mark> |
| Female gender | 275 (76.4%) | 235 (79.1%) | 510 (77.6%) | 0.403 |
| Race | | | | 0.562 |
| Caucasian | 208(57.9%) | 178(59.9%) | 368(58.8%) | |
| African American | 99(27.6%) | 73(24.6%) | 172(26.2%) | |
| Hispanic | 47(13.1%) | 38(12.8%) | 85(13.0%) | |
| Other | 5(1.4%) | 8(2.7%) | 13(2.0%) | |
| Hypertension | 186 (51.7%) | 142 (47.8%) | 328 (49.9%) | 0.326 |
| Diabetes | <mark>97 (26.9%)</mark> | <mark>91 (30.6%)</mark> | <mark>188 (28.6%)</mark> | <mark>0.297</mark> |
| OSA | 216 (60.0%) | 176 (59.3%) | 392 (59.7%) | 0.847 |
| GERD | 256 (71.1%) | 191 (64.3%) | 447 (68.0%) | 0.063 |
| OA | 111 (30.8%) | 85 (28.6%) | 196 (29.8%) | 0.537 |

| ; | | Pre Intervention (N=360) | Post Intervention (N=297) | Overall (N=657) | P- valu e |
|---|--------------------|-----------------------------|---------------------------------|------------------------|--------------------|
| | Post-op ED visit | <mark>12 (3.3%)</mark> | <mark>12 (4.0%)</mark> | <mark>24 (3.7%)</mark> | <mark>0.631</mark> |
| | Reoperation | <mark>9 (2.5%)</mark> | <mark>8 (2.7%)</mark> | <mark>17 (2.6%)</mark> | <mark>0.876</mark> |
| | Bariatric Revision | 78 (21.7%) | 65 (21.9%) | 143 (21.8%) | 0.961 |



Results: Length of Stay

- Reduced by 1 day
- No change in readmission or complication rate

| Outcomes | Pre Intervention | Post Intervention | P-value |
|------------------------------|------------------|----------------------|---------|
| Length of Stay, median (IQR) | 2.0 (1.0 - 2.0) | 1.0 (1.0 - 2.0) | <0.001 |
| Readmission | 16 (4.4%) | 16 (5.4%) | 0.577 |
| Complication | 15 (4.2%) | 19 (6.4%) | 0.199 |
| | | | |




LOS Continued

| Factors | IRR(95% Confidence Interval) | P-value |
|---|---------------------------------|--------------------|
| Group (Post Intervention vs. Pre Intervention) | <mark>0.74(0.65-0.85)</mark> | <0.001 |
| Age | 1.01(1.0-1.02) | 0.145 |
| BMI | 0.99(0.98-1.01) | 0.255 |
| Sex (Female vs. Male) | 1.11(0.96-1.29) | 0.169 |
| Race (White vs. other) | 0.90(0.76-1.05) | 0.191 |
| HTN | 0.96(0.81-1.14) | 0.682 |
| DM | <mark>1.22(1.05-1.42)</mark> | <mark>0.018</mark> |
| OSA | 0.97(0.83-1.15) | 0.745 |
| GERD | 1.07(0.97-1.18) | 0.19 |
| OA | 1.14(0.95-1.36) | 0.194 |



Results: Discharge Opioid Prescriptions





Discussion

- Great improvement in discharge opioid prescriptions
 - Continued patient education and protocol optimization to further decrease opioid use
- Collection and interpretation of immediate post-operative opioid use
- Long term opioid use data



Conclusion

- ERAS and BSTOP protocols reduced length stay and opioid use without increasing complications or readmissions.
- Impact on other foregut surgery procedures should be evaluated.





THANK YOU

